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ABSTRACT

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays, systems, methods and kits for the
age determination of an individual from bloodstains or
samples of unknown origin. The methodology is based on
gene expression profiling analysis in which novel human
newborn fetal specific genes are identified by detecting the
presence of appropriate messenger RNA species.
16 Claims, 14 Drawing Sheets
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HBGl
acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa
ggtgctgacttccttgggagatgccacaaagcacctggatgatctcaagggcacctttgcccagctgagtgaactgcactgtgac
aagctgcatgtggatcctgagaacttcaagctcctgggaaatgtgctggtgaccgttttggcaatccatttcggcaaagaattcac
ccctgaggtgcaggcttcctggcagaagatggtgactgcagtggccagtgccctgtcctccagataccactgagctcactgccc
atgattcagagctttcaaggataggctttattctgcaagcaatacaaataataaatctattctgctgagagatcac

Figure 1
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HBG2

acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa
ggtgctgacttccttgggagatgccataaagcacctggatgatctcaagggcacctttgcccagctgagtgaactgcactgtgac
aagctgcatgtggatcctgagaacttcaagctcctgggaaatgtgctggtgaccgttttggcaatccatttcggcaaagaattcac
ccctgaggtgcaggcttcctggcagaagatggtgactggagtggccagtgccctgtcctccagataccactgagctcactgccc
atgatgcagagctttcaaggataggctttattctgcaagcaatcaaataataaatctattctgctaagagatcac

Figure 2
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HBGln

acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa
ggtgctgacttccttgggagatgccacaaagcacctggatgattcagagctttcaaggataggctttattctgcaagcaatacaaat
aataaatctattctgctgagagatcac

Sequence ID 1

Figure 3

U.S. Patent

Oct. 2, 2007

Sheet 4 of 14

US 7,276,340 Bl

HBG2n

acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcamcacagaggaggacaaggctac
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa
ggtgctgacttccttgggagatgccataaagcacctggatgatctcaagggcaccmgcccagctgagtgaactgcactgagct
cactgcccatgatgcagagcmcaaggataggctttattctgcaagcaatcaaataataaatctattctgctaagagatcac

Sequence ID 2

Figure 4
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SIS

ggcagtctcgcgataactgcgcaggcgcggaccaaagcgatctcttctgaggatccggcaagatggcagaagtagagcagaa
gaagaagcggaccttccgcaagttcacctaccgcggcgtggacctcgaccagctgctggacatgtcctacgagcagctgatgc
agctgtacagtgcgcgccagcggcggcggctgaaccggggcctgcggcggaagcagcactccctgctgaagcgcctgcgc
aaggccaagaaggaggcgccgcccatggagaagccggaagtggtgaagacgcacctgcgggacatgatcatcctacccga
gatggtgggcagcatggtgggcgtctacaacggcaagaccttcaaccaggtggagatcaagcccgagatgatcggccactac
ctgggcgagttctccatcacctacaagcccgtaaagcatggccggcccggcatcggggccacccactcctcccgcttcatccct
ctcaagtaatggctcagctaataaaggcgcacatgactcc

Sequence ID 3

Figure 5
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F 5' gaa-agc-tct-gaa-tca-tcc-agg-tg 3'
Sequence ID 4

Figure 6
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6FAM-ttt-gtg-gca-tct-ccc-aag-gaa-gtc-agc MGBNFQ

Sequence ID 5

Figure 7
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R 5' agt-caa-ggc-aca-tgg-caa-gaa-g 3'

Sequence ID 6

Figure 8
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F 5' gca-gtg-agc-tca-gtg-cag-ttc 3'

Sequence ID 7

Figure 9
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6FAM-caa-agg-tgc-cct-tga-gat-cat-cca-gg MGBNFQ

Sequence ID 8

Figure 10
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R 5' ttc-ctt-ggg-aga-tgc-cat-aaa 3'

Sequence ID 9

Figure 11
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F 5' cca-aag-cga-tct-ctt-ctg-agg-at 3

Sequence ID 10

Figure 12
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VIC-cgg-caa-gat-ggc-aga-agt-aga-gca-gaa MGBNFQ

Sequence ID 11

Figure 13
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R 5' acg-ccg-cgg-tag-gtg-aa

Sequence ID 12

Figure 14
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AGE DETERMINATION FROM
BIOLOGICAL STAINS USING MESSENGER
RNA PROFILING ANALYSIS

Numerous molecular theories have been investigated for
their correlation with human ageing. Postulated molecular
mechanisms include, inter alia, progressive damage to DNA,
telomere shortening, long-lived protein glycation and reactive oxygen species (ROS)-mediated oxidative damage to
macromolecules. A major downfall to these approaches is
that they are characterized by the "degenerative" ageing
process, whereby as individuals increase in age the amount
of damage also increases, this is especially characteristic of
older aged individuals. From the forensic standpoint, however, it would be useful to be able to distinguish between
individuals of all age groups and this may require the
detection of more subtle molecular changes. An alternate
approach to age determination relies on epigenetic and
developmental control of gene expression through messenger RNA (mRNA) profiling analysis. This theory of"developmental" ageing, would allow individuals to be categorized
into various age groups, each correlated with a specific stage
of human development.
The life-cycle of humans comprises a number of developmentally recognized stages. As the human proceeds
through these developmental stages, sub-sets of the 20-50
thousand human genes will be differentially expressed.
Determining the global gene expression profile (or differential mRNA gene expression profile) present in a biological
stain could reveal constellations of genes whose expression
is correlated with a specific age. For example, identifying
fetal hemoglobin (HBG) and fetal specific regulating mRNA
species, isolating pubertal and pre-pubertal hormones and
receptors or assaying for DNA damage and repair factors
would be indicative of newborn babies, adolescent teenagers
and elderly individuals, respectively.

This invention claims the benefit of priority from U.S.
Provisional Application Ser. No. 60/612,233 filed Sep. 22,
2004 the content of which is incorporated herein by reference.

5

FIELD OF THE INVENTION

10

This invention relates to a ribonucleic acid (RNA) based
assay system for determining the biological age of an
individual from which a body fluid originated.
15

SEQUENCE LISTING
Appendix A is a sequence listing of mRNA and DNA
sequences identified in FIGS. 1-14, the content of Appendix
A is also submitted on a compact disc and is incorporated
herein by reference. Attached hereto is one compact disc
containing the following files:
SEQ. 1 provides the mRNA sequence of HBGl
SEQ. 2 provides the mRNA sequence of HBG2
SEQ. 3 provides the mRNA sequence ofHBGln (Seq. ID
1)
SEQ. 4 provides the mRNA sequence ofHBG2n (Seq. ID
2)
SEQ. 5 provides the mRNA sequence of S15 (Seq. ID 3)
SEQ. 6 provides the DNA sequence of an HBG ln primer
(Seq. ID 4)
SEQ. 7 provides the DNA sequences of an HBG ln probe
(Seq. ID 5)
SEQ. 8 provides the DNA sequences of an HBG ln primer
(Seq. ID 6)
SEQ. 9 provides the DNA sequences of an HBG2n primer
(Seq. ID 7)
SEQ. 10 provides the DNA sequences of an HBG2n probe
(Seq. ID 8)
SEQ. 11 provides the DNA sequences of an HBG2n
primer (Seq. ID 9)
SEQ. 12 provides the DNA sequences of an S15 primer
(Seq. ID 10)
SEQ. 13 provides the DNA sequences of an S15 probe
(Seq. ID 11)
SEQ. 14 provides the DNA sequences of an S15 primer
(Seq. ID 12)

20
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SUMMARY OF THE INVENTION
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BACKGROUND AND PRIOR ART
50

It is now a routine matter for forensic scientists to obtain

the genetic profile of an individual from deoxyribonucleic
acid (DNA) recovered from a biological stain deposited at a
crime scene. However, in certain instances where there is no
developed suspect as yet or there is no match with any
database sample, the DNA profile per se provides no meaningful information to investigators, with the notable exception of gender determination. To aid in these investigations
another useful biometric that could provide important probative information is the biological age of an individual. For
example, the ability to provide investigators with information as to whether a DNA donor is a newborn baby, an
adolescent teenager or an elderly individual could be useful
in certain cases, particularly those involving young children
such as kidnappings or in providing additional intelligence
during terrorist investigations. Currently no reliable validated molecular tests are available for age determination.

55

60

65

A primary objective of the present invention is to provide
two novel newborn specific fetal hemoglobin genes.
A second objective of the present invention is to provide
an mRNA based method for identifying the newborn specific
genes present in a bloodstain.
A third objective of the present invention is to provide a
kit for the analysis of bloodstains to determine if a particular
bloodstain originated from a newborn individual.
A preferred method for identifying whether a stain contains blood of a newborn human being, includes, obtaining
a sample stain consisting of a body fluid from a human
being, extracting total ribonucleic acid (tRNA) from the
sample stain, treating the total RNA with an enzyme, initiating a reverse-transcription (RT) reaction by treating total
RNA with random decamer primers and a reverse transcriptase enzyme to produce cDNA, amplifying the cDNA
using HBGv-specific and HSK primers with corresponding
fluorescently labeled probes, identifying the age of the donor
by determining the cycle threshold (Ct) value of a housekeeping gene (HSK) and the Ct value of the HBGv target
gene, then subtracting the Ct value of the target gene, from
the Ct value of the HSK gene, wherein a positive value
would indicate that the blood originates from a newborn
human being.
A more preferred method uses the reverse transcriptase
enzyme, Moloney Murine Leukemia Virus (MMLV-RT) and
has 2 variants of hemoglobin (HBG) used as primers. The 2
variants ofHBG are HBG ln and HBG2n and the primers are
segments of HBGln and HBG2n. More preferably, the
primers are one or more selected from the sequence ID 4, 5,
6, 7, 8, 9, 10, 11 or 12.

US 7,276,340 Bl
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The preferred identifying probes fluoresce and the values
are determined by finding the Ct of the HSK and the Ct of
each of the variants of HBG and then subtracting the Ct of
the HBGv from the Ct of the HSK, generating a dCt value.
The HSK is the ribosomal protein, S15 and the age of the
newborn is less than 1 week old or the age of the newborn
can be less than 5 months old. More preferably, the HSK is
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The preferred extracting procedure for the total RNA uses
a denaturing solution such as guanidine isothiocyanatephenol:chloroform. Preferably, the extracted total RNA is
precipitated with an organic solvent, such as, isopropanol.
The preferred enzyme used to treat the extracted total RNA
is deoxyribonuclease I (DNase I).
A preferred gene coding for the human newborn specific
fetal hemoglobin variant is HBGln as in SEQ ID 1 and
HBG2n as in SEQ ID 2.
Another preferred gene coding for the human newborn
specific fetal hemoglobin variants are HBGln and HBG2n
and polymorphisms thereof.
A preferred kit for use in determining the biological age
of an individual in an unknown bloodstain, uses HBG ln and
HBG2n and HSK specific primers, preferably, selected from
one or more of sequence ID 4, 5, 6, 7, 8, 9, 10, 11, or 12; the
preferred housekeeping gene is the ribosomal protein, S15.
The preferred probes are labeled with fluorescent dyes.
Further objects and advantages of this invention will be
apparent from the following detailed description and
example of a presently preferred embodiment.

The life-cycle of humans comprises a number of developmentally recognized stages. As the human proceeds
through these developmental stages, sub-sets of the 20-50
thousand human genes will be differentially expressed.
Determining the global gene expression profile (or differential mRNA gene expression profile) present in a biological
stain could reveal constellations of genes whose expression
is correlated with a specific age. For example, identifying
fetal hemoglobin and fetal specific regulating mRNA species, isolating pubertal and pre-pubetal hormones and receptors or assaying for DNA damage and repair factors, would
be indicative of newborn babies, adolescent teenagers and
elderly individuals, respectively.
A clear example of age related differential gene expression involves the fetal to adult hemoglobin shift. The human
beta-hemoglobin locus is located on the short arm of chromosome 11 (llp15.5), and encodes five functional beta-like
globin genes: epsilon, gammaG, ganmiaA, delta, and beta,
(hemoglobin gamma mRNA sequences, HBGl (gammaA)
and HBG2 (gammaG), are provided in FIG. 1 and FIG. 2,
respectively).
The expression of embryonic hemoglobin (epsilon) commences in the yolk sac in the early stages of gestational
development. During the fifth week of gestation the fetal
liver, spleen and bone marrow begin to express the fetal
specific gamma hemoglobin chains (gammaA and gammaG)
to form the fetal hemoglobin protein. This up-regulation of
ganmia-globin is accompanied by a shutdown of epsilonglobin synthesis. Shortly before birth, beta-globin gene
expression commences in the bone marrow, forming adult
hemoglobin and inturn ganmia-globin expression is down
regulated. Therefore, the development of an assay which
identifies gamma hemoglobin mRNA in a biological stain,
would indicate that the donor of the stain is a newborn baby.
The gamma hemoglobin locus was analyzed by reverse
transcription-polymerase chain reaction (RT-PCR) using
two sets of highly specific primers, one designed to specifically amplify HBGl (gammaA) and one designed for amplification of HBG2 (gammaG). In contrast to our initial
hypothesis, a messenger RNA (mRNA) product corresponding to the individual HBG 1 or HBG2 genes was amplified in
all age groups tested. These results demonstrated that the
production of gamma hemoglobin mRNA is not restricted to
the fetal and newborn stages of development. Upon further
investigation of these RT-PCR assays, the presence of an
additional lower molecular weight amplimer was detected in
only newborn individuals. These lower molecular weight
products were excised, cloned, sequenced and aligned with
the standard hemoglobin genes. Alignment analysis revealed
these lower molecular weight amplimers to be variants of
the standard gamma hemoglobin genes (HBGv) which we
have termed HBGln and HBG2n (variant ganmia hemoglobin mRNA sequences HBGln and HBG2n are provided in
FIG. 3 and FIG. 4, respectively).
Based on this process the invention provides real-time
PCR duplexes which are composed of one novel newborn
specific fetal hemoglobin variant, HBG ln or HBG2n, whose
sequences are identified as SEQUENCE ID 1 (HBGln)
(FIG. 3), SEQUENCE ID 2 (HBG2n) (FIG. 4), and one
housekeeping gene (HSK), which may be the ribosomal
protein, Sl 5, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) or others (example of a HSK gene sequence, Sl 5,
(SEQUENCE ID 3) (FIG. 5)). The collection of genes that
are expressed within the constellation of differentiated cells
that make up a body fluid is called the multicellular transcriptome. These genes comprise ubiquitously expressed
housekeeping (HSK) genes, which are responsible for cell
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BRIEF DESCRIPTION OF THE FIGURES
FIG.
FIG.
FIG.
FIG.
FIG.
FIG.
FIG.
FIG.
FIG.
FIG.
FIG.
FIG.
FIG.
FIG.

1 provides the mRNA sequence of HBGl
2 provides the mRNA sequence of HBG2
3 provides the mRNA sequence of HBGln
4 provides the mRNA sequence of HBG2n
5 provides the mRNA sequence of S15
6 provides the DNA sequence of an HBGln primer

7 provides the DNA sequences of an HBG 1 n probe
8 provides the DNA sequences of an HBG ln primer
9 provides the DNA sequences of an HBG2n primer
10 provides the DNA sequences of an HBG2n probe
11 provides the DNA sequences of an HBG2n primer
12 provides the DNA sequences of an S15 primer
13 provides the DNA sequences of an S15 probe
14 provides the DNA sequences of an S15 primer
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DESCRIPTION OF THE PREFERRED
EMBODIMENTS
50

Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
particular arrangements shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
Below is a listing of several acronyms used herein:
DNA is deoxyribonucleic acid
Ct is cycle threshold value; it is the cycle number at which
the fluorescent signal passes a pre-determined threshold.
HBG is hemoglobin
HSK is housekeeping gene
RNA is ribonucleic acid
mRNA is messenger ribonucleic acid
ROS is reactive oxygen species
RT-PCR is reverse transcription polymerase chain reaction
S 15 is ribosomal protein

55
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maintenance functions independent of biological age, and
genes that are specifically expressed in an age dependent
manner.
Fluorescent (i.e. FAM (6-carboxyfluorescein) and VIC)
dye-labeled probes (i.e. minor groove binding non-fluorescent quencher (MGBNFQ)) and their corresponding unlabeled primers are incorporated into the real-time PCR
(qPCR) reaction. These qPCR duplexes have been optimized to determine if a bloodstain originated from a newborn individual and are sensitive with as little as 50 pg of
input RNA (into the qPCR reaction). The real-time qPCR
methodology is based on determining the delta cycle threshold (dCt) values generated using the cycle threshold (Ct) of
the HSK gene and the Ct of the novel hemoglobin variants
(HBGv) (dCt=Ct S15-Ct HBGv). A positive dCt value
would indicate a newborn origin; in contrast a negative dCt
value would be obtained with all other ages.
An mRNA based approach for age determination, such as
the real time PCR assays described above, could allow the
facile identification of the newborn specific genes present in
a bloodstain and could rapidly become a validated molecular
test for newborn specific age determination.
As an example, the assay of the invention can be performed in two fashions: one in which the newborn is
identified as less than 1 week old; the other as less than 5
months old, depending on the amount of material used.
The following example provides further explanation of
the present invention.

ing the presence of appropriate mRNA species. The genespecific primers are incorporated with fluorescently labeled
probes (i.e. FAM and VIC) into a single multiplexed quantitative polymerase chain reaction (qPCR). The mRNA is
amplified and this amplification is detected by determining
the fluorescent emission of the dye-labeled probe.

EXAMPLE 1
For RNA isolation, total RNA is extracted from a bloodstain using a denaturing solution, composed of guanidine
isothiocyanate, the RNA is isolated with acid phenol:chloroform and precipitated with isopropanol and GlycoB!ue™
glycogen carrier (fromAmbion Inc., Austin, Tex.). The RNA
is centrifuged and the pellet is washed once with a 75%
ethanol/25% DEPC-treated water solution. The pellet is
dried, re-solubilized and stored in an RNAsecure Resuspension Solution (Ambion Inc., Austin, Tex.). Next, the
extracted total RNA is treated with an enzyme, deoxyribonuclease I (TURBO™ DNase (RNase-Free)) (Ambion Inc.,
Austin, Tex.), quantitated using the unsymmetrical cyanine
dye RiboGreen® (Molecular Probes, Eugene, Oreg.) and
then reverse-transcribed using fifty micromolar random
decamers as the first strand primer, producing complementary DNA (cDNA). The Moloney Murine Leukemia VirusReverse Transcriptase enzyme (MMLV-RT) from Ambion
Inc., Austin, Tex., was used in this case. Finally, the cDNA
is amplified using housekeeping and newborn gene-specific
primers (as exemplified in FIGS. 6-14).
Based on the above extraction and purification technique,
duplex real-time PCR assays using in this case the Taqman®
Universal PCR Master Mix in the 7000 Sequence detection
System from Applied Biosystems, Foster City, Calif., and
standard cycling conditions such as: Step 1: 1 cycle of 50
degrees C., for 2:00 minutes; Step 2: 1 cycle of 95 degrees
C., for 10:00 minutes; Step 3: 40-50 cycles of 95 degrees C.,
for 0: 15 seconds and 60 degrees C., for 1:00 minute; wherein
data is collected at stage 3, step 2 (60 degrees C., for 1:00)
were developed which can definitively identify newborn
RNA. These duplex reactions are composed of one of the
two novel variant forms of newborn gamma hemoglobin
(HBGv), HBGln or HBG2n, and a housekeeping (HSK)
gene, the ribosomal protein, S15 and have been optimized
for the detection of newborn individuals from bloodstains.
The methodology is based on gene expression profiling
analysis in which the HBGv genes are identified by detect-

5

EXAMPLE 2
10

In an assay of the invention which identifies newborns
that are from 1 hour to 1 week in biological age one may
proceed as Example 1 above using:
HBGln

15

50 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
HBG2n

20

50 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
S15

25

900 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
EXAMPLE 3
30

In an assay of the invention which identifies newborns
that are from 1 hour to 5 months in biological age one may
proceed as in Example I above using:
HBGln

35

100 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
HBG2n

40

50 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
S15

45

600 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
50

EXAMPLE 4

55

The cycle threshold (Ct) values obtained are used to determine the delta Ct (dCt) for that particular sample. The
equation for dCt calculation is:
Ct(S 15)-Ct(HBG ln)~dCt
Ct(S 15)-Ct(HBG2n)~dCt

60

If the dCt value is positive then the sample originated from
a newborn.
If the dCt value is negative then the sample originated from
an age other than newborn.

65

If no Ct value is generated with the newborn genes (HBG ln
or HBG2n) the sample is given a Ct value of 40.000 (the
maximum number of cycles), for that particular gene. If no

US 7,276,340 Bl
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Ct value is generated with the housekeeping gene (S15) than
the assay must be repeated.
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope

of the invention is not intended to be, nor should it be
deemed to be, limited thereby and such other modifications
or embodiments as may be suggested by the teachings herein
are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 14
<210>
<211>
<212>
<213>

SEQ ID NO
LENGTH: 584
TYPE: DNA
ORGANISM: HBGl

<400> SEQUENCE:
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc

60

atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag

120

atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct

180

ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg

240

cacatggcaa gaaggtgctg acttccttgg gagatgccac aaagcacctg gatgatctca

300

agggcacctt tgcccagctg agtgaactgc actgtgacaa gctgcatgtg gatcctgaga

360

acttcaagct cctgggaaat gtgctggtga ccgttttggc aatccatttc ggcaaagaat

420

tcacccctga ggtgcaggct tcctggcaga agatggtgac tgcagtggcc agtgccctgt

480

cctccagata ccactgagct cactgcccat gattcagagc tttcaaggat aggctttatt

540

ctgcaagcaa tacaaataat aaatctattc tgctgagaga tcac

584

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH: 583
TYPE: DNA
ORGANISM: HGB2

<400> SEQUENCE: 2
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc

60

atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag

120

atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct

180

ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg

240

cacatggcaa gaaggtgctg acttccttgg gagatgccat aaagcacctg gatgatctca

300

agggcacctt tgcccagctg agtgaactgc actgtgacaa gctgcatgtg gatcctgaga

360

acttcaagct cctgggaaat gtgctggtga ccgttttggc aatccatttc ggcaaagaat

420

tcacccctga ggtgcaggct tcctggcaga agatggtgac tggagtggcc agtgccctgt

480

cctccagata ccactgagct cactgcccat gatgcagagc tttcaaggat aggctttatt

540

ctgcaagcaa tcaaataata aatctattct gctaagagat cac

583

<210>
<211>
<212>
<213>

SEQ ID NO 3
LENGTH: 367
TYPE: DNA
ORGANISM: HBGln

<400> SEQUENCE:
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc

60

atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag

120

atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct

180

US 7,276,340 Bl
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-continued
ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg

240

cacatggcaa gaaggtgctg acttccttgg gagatgccac aaagcacctg gatgattcag

300

agctttcaag gataggcttt attctgcaag caatacaaat aataaatcta ttctgctgag

360

agatcac

367

<210>
<211>
<212>
<213>

SEQ ID NO 4
LENGTH: 421
TYPE: DNA
ORGANISM: HBG2n

<400> SEQUENCE:
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc

60

atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag

120

atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct

180

ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg

240

cacatggcaa gaaggtgctg acttccttgg gagatgccat aaagcacctg gatgatctca

300

agggcacctt tgcccagctg agtgaactgc actgagctca ctgcccatga tgcagagctt

360

tcaaggatag gctttattct gcaagcaatc aaataataaa tctattctgc taagagatca

420

c

421

<210>
<211>
<212>
<213>

SEQ ID NO 5
LENGTH: 531
TYPE: DNA
ORGANISM: Sl5

<400> SEQUENCE: 5
ggcagtctcg cgataactgc gcaggcgcgg accaaagcga tctcttctga ggatccggca

60

agatggcaga agtagagcag aagaagaagc ggaccttccg caagttcacc taccgcggcg

120

tggacctcga ccagctgctg gacatgtcct acgagcagct gatgcagctg tacagtgcgc

180

gccagcggcg gcggctgaac cggggcctgc ggcggaagca gcactccctg ctgaagcgcc

240

tgcgcaaggc caagaaggag gcgccgccca tggagaagcc ggaagtggtg aagacgcacc

300

tgcgggacat gatcatccta cccgagatgg tgggcagcat ggtgggcgtc tacaacggca

360

agaccttcaa ccaggtggag atcaagcccg agatgatcgg ccactacctg ggcgagttct

420

ccatcaccta caagcccgta aagcatggcc ggcccggcat cggggccacc cactcctccc

480

gcttcatccc tctcaagtaa tggctcagct aataaaggcg cacatgactc c

531

<210>
<211>
<212>
<213>

SEQ ID NO 6
LENGTH: 23
TYPE: DNA
ORGANISM: HBGln

<400> SEQUENCE:
gaaagctctg aatcatccag gtg

<210>
<211>
<212>
<213>

23

SEQ ID NO 7
LENGTH: 27
TYPE: DNA
ORGANISM: HBGln

<400> SEQUENCE:
tttgtggcat ctcccaagga agtcagc

27

US 7,276,340 Bl
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-continued
<210>
<211>
<212>
<213>

SEQ ID NO 8
LENGTH: 22
TYPE: DNA
ORGANISM: HBGln

<400> SEQUENCE:
agtcaaggca catggcaaga ag

<210>
<211>
<212>
<213>

22

SEQ ID NO 9
LENGTH: 21
TYPE: DNA
ORGANISM: HBG2n

<400> SEQUENCE:
21

gcagtgagct cagtgcagtt c

<210>
<211>
<212>
<213>

SEQ ID NO 10
LENGTH: 26
TYPE: DNA
ORGANISM: HBG2n

<400> SEQUENCE: 10
caaaggtgcc cttgagatca tccagg

<210>
<211>
<212>
<213>

26

SEQ ID NO 11
LENGTH: 21
TYPE: DNA
ORGANISM: HBG2n

<400> SEQUENCE: 11
21

ttccttggga gatgccataa a

<210>
<211>
<212>
<213>

SEQ ID NO 12
LENGTH: 23
TYPE: DNA
ORGANISM: SlS

<400> SEQUENCE: 12
ccaaagcgat ctcttctgag gat

<210>
<211>
<212>
<213>

23

SEQ ID NO 13
LENGTH: 27
TYPE: DNA
ORGANISM: SlS

<400> SEQUENCE: 13
cggcaagatg gcagaagtag agcagaa

<210>
<211>
<212>
<213>

27

SEQ ID NO 14
LENGTH: 17
TYPE: DNA
ORGANISM: SlS

<400> SEQUENCE: 14
acgccgcggt aggtgaa

We claim:
1. A method for identifying whether a stain contains blood
of a newborn human being, comprising the steps of:
a) obtaining a sample stain comprising blood from a
human being;
b) extracting total ribonucleic acid (tRNA) from the
sample stain;

17

60

65

c) treating the total RNA with an enzyme;
d) initiating a reverse-transcription (RT) reaction by treating total RNA with random decamer primers and a
reverse transcriptase enzyme to produce cDNA;
e) amplifying the cDNA using HBGv-specific primers
consisting of SEQ ID NO: 9 and SEQ ID NO: 7 and

US 7,276,340 Bl
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HSK primers with corresponding fluorescently labeled
probes;
f) identifying the age of the donor by determining the
cycle threshold (Ct) value of a housekeeping gene
(HSK) and the Ct value of the HBGv target gene, then
subtracting the Ct value of the target gene, from the Ct
value of the HSK gene, wherein a positive value would
indicate that the blood originates from a newborn
human being.
2. The method, as in claim 1, wherein the reverse transcriptase enzyme is Moloney Murine Leukemia Virus
(MMLV-RT).
3. A method, as in claim 1, wherein 2 variants of hemoglobin (HBG) are used as primers.
4. A method, as in claim 3, wherein the 2 variants ofHBG
are HBGln and HBG2n.
5. A method, as in claim 4 wherein the primers are
segments ofHBGln and HBG2n.
6. A method, as in claim 5 wherein the primers are one or
more selected from the group consisting of sequence ID 4,
5, 6, 7, 8, 9, 10, 11 and 12.
7. A method, as in claim 5 wherein the identifying probes
fluoresce and the values are determined by finding the Ct of
the HSK and the Ct of each of the variants of HBG and then

subtracting the Ct of the HBGv from the Ct of the HSK,
generating a dCt value.
8. A method, as in claim 5, wherein the HSK is the
ribosomal protein, S15.
9. A method, as in claim 5, wherein the age of the newborn
is less than 1 week old.
10. A method, as in claim 5, wherein the age of the
newborn is less than 5 months old.
11. A method, as in claim 5, wherein the HSK is glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
12. The method of claim 1, wherein the total RNA is
extracted with a denaturing solution.
13. The method of claim 1, wherein the extracting procedure is guanidine isothiocyanate-phenol:chloroform.
14. The method of claim 1, wherein the extracted total
RNA is precipitated with an organic solvent.
15. The method of claim 1, wherein the organic solvent is
isopropanol.
16. The method of claim 1, wherein the enzyme used to
treat the extracted total RNA is deoxyribonuclease I (DNase
I).

5

10

15

20

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION
PATENT NO.
APPLICATION NO.
DATED
INVENTOR(S)

: 7,276,340 Bl
: 11/232313
: October 2, 2007
: John Ballantyne

Page 1of1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 1 lines 3-4 insert:
--STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This subject invention was made with government support by Technical Support Working Group on
Counter Terrorism (TSWG), federal contract number TSWG Task IS-F0-159. The government has
certain rights in this invention.--

Signed and Sealed this
Fifteenth Day of March, 2011

ffa:.1 J:•k~
David J. Kappos
Director of the United States Patent and Trademark Office

